It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Regulatory T cells (Tregs) are a type of lymphocyte that is key to maintaining immunological self-tolerance, with great potential for therapeutic applications. A long-standing challenge in the study of Tregs is that the only way they can be unambiguously identified is by using invasive intracellular markers. Practically, the purification of live Tregs is often compromised by other cell types since only surrogate surface markers can be used. We present here a non-invasive method based on Raman spectroscopy that can detect live unaltered Tregs by coupling optical detection with machine learning implemented with regularized logistic regression. We demonstrate the validity of this approach first on murine cells expressing a surface Foxp3 reporter, and then on peripheral blood human T cells. By including methods to account for sample purity, we could generate reliable models that can identify Tregs with an accuracy higher than 80%, which is already comparable with typical sorting purities achievable with standard methods that use proxy surface markers. We could also demonstrate that it is possible to reliably detect Tregs in fully independent donors that are not part of the model training, a key milestone for practical applications.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Immunology Frontier Research Center (IFReC), Osaka University, Biophotonics Laboratory, Suita, Japan (GRID:grid.136593.b) (ISNI:0000 0004 0373 3971)
2 Osaka University, Experimental Immunology, Immunology Frontier Research Center (IFReC), Suita, Japan (GRID:grid.136593.b) (ISNI:0000 0004 0373 3971)
3 Osaka University, Experimental Immunology, Immunology Frontier Research Center (IFReC), Suita, Japan (GRID:grid.136593.b) (ISNI:0000 0004 0373 3971); Osaka University, Department of Frontier Research in Tumor Immunology, Graduate School of Medicine, Suita, Japan (GRID:grid.136593.b) (ISNI:0000 0004 0373 3971)
4 The University of Tokyo, Laboratory of Immunology and Microbiology, Graduate School of Pharmaceutical Sciences, Tokyo, Japan (GRID:grid.26999.3d) (ISNI:0000 0001 2169 1048)
5 Osaka University, Experimental Immunology, Immunology Frontier Research Center (IFReC), Suita, Japan (GRID:grid.136593.b) (ISNI:0000 0004 0373 3971); Kyoto University, Laboratory of Experimental Immunology, Institute for Life and Medical Sciences, Kyoto, Japan (GRID:grid.258799.8) (ISNI:0000 0004 0372 2033)
6 Immunology Frontier Research Center (IFReC), Osaka University, Biophotonics Laboratory, Suita, Japan (GRID:grid.136593.b) (ISNI:0000 0004 0373 3971); Osaka University, Center for Infectious Disease Education and Research (CiDER), Suita, Japan (GRID:grid.136593.b) (ISNI:0000 0004 0373 3971); Osaka University, Open and Transdisciplinary Research Institute (OTRI), Suita, Japan (GRID:grid.136593.b) (ISNI:0000 0004 0373 3971)